TY  - JOUR
AB  - Patients after solid organ transplantation (SOT) carry a substantially increased risk to develop malignant lymphomas. This is in part due to the immunosuppression required to maintain the function of the organ graft. Depending on the transplanted organ, up to 15% of pediatric transplant recipients acquire posttransplant lymphoproliferative disease (PTLD), and eventually 20% of those succumb to the disease. Early diagnosis of PTLD is often hampered by the unspecific symptoms and the difficult differential diagnosis, which includes atypical infections as well as graft rejection. Treatment of PTLD is limited by the high vulnerability towards antineoplastic chemotherapy in transplanted children. However, new treatment strategies and especially the introduction of the monoclonal anti-CD20 antibody rituximab have dramatically improved outcomes of PTLD. This review discusses risk factors for the development of PTLD in children, summarizes current approaches to therapy, and gives an outlook on developing new treatment modalities like targeted therapy with virus-specific T cells. Finally, monitoring strategies are evaluated.
AU  - Mynarek, M.*
AU  - Schober, T.*
AU  - Behrends, U.
AU  - Maecker-Kolhoff, B.*
C1  - 28076
C2  - 32915
TI  - Posttransplant lymphoproliferative disease after pediatric solid organ transplantation.
JO  - Clin. Dev. Immunol.
VL  - 2013
PB  - Hindawi Publishing
PY  - 2013
SN  - 1740-2522
ER  - 

TY  - JOUR
AB  - Cellular retinaldehyde binding protein (CRALBP) is an autoantigen in spontaneous equine recurrent uveitis. In order to test whether CRALBP contributes to human autoimmune uveitis, the specificity of antibodies from human uveitis patient's sera was first evaluated in two-dimensional (2D) Western blot analysis. Subsequent identification of the immunoreactive proteins by mass spectrometry resulted in the identification of CRALBP as a putative autoantigen. Additionally, sera from human uveitis and control patients were by Western blot using purified human recombinant CRALBP. Anti-CRALBP autoantibodies occur more frequently (P<.01) in human uveitis patients than in normal controls. Thirty out of 56 tested uveitis patient's sera contained autoantibodies reactive against CRALBP, compared to only four out of 23 normal control subjects. The presence of CRALBP autoantibodies in 54% of tested uveitis patients supports CRALBP as a possible autoantigen in human autoimmune uveitis.
AU  - Deeg, C.A.*
AU  - Raith, A.J.*
AU  - Amann, B.*
AU  - Crabb, J.W.*
AU  - Thurau, S.R.*
AU  - Hauck, S.M.
AU  - Ueffing, M.
AU  - Wildner, G.*
AU  - Stangassinger, M.*
C1  - 22927
C2  - 24866
TI  - CRALBP is a highly prevalent autoantigen for human autoimmune uveitis.
JO  - Clin. Dev. Immunol.
VL  - 2007
PB  - Hindawi Publishing
PY  - 2007
SN  - 1740-2522
ER  - 

TY  - JOUR
AU  - Wjst, M.
C1  - 4631
C2  - 22301
SP  - 175-180
TI  - The triple T allergy hypothesis.
JO  - Clin. Dev. Immunol.
VL  - 11
PY  - 2004
SN  - 1740-2522
ER  -